Details of the Drug | DrugMAP

General Information of Drug (ID: DM5YG02)

Drug Name

PF-06263276

Indication

Disease Entry	ICD 11	Status	REF
Psoriasis vulgaris	EA90	Phase 1	[1]
------------------------------------------------------------------------------------

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C31H31FN8O2
Canonical SMILES: CCC1=CC(=C(C=C1C2=CC3=C(C=C2)C(=NN3)C4=NC5=C(N4)CN(CC5)C(=O)C6=CN=C(C=N6)N7CCCCC7)F)O
InChI: 1S/C31H31FN8O2/c1-2-18-13-27(41)22(32)14-21(18)19-6-7-20-24(12-19)37-38-29(20)30-35-23-8-11-40(17-26(23)36-30)31(42)25-15-34-28(16-33-25)39-9-4-3-5-10-39/h6-7,12-16,41H,2-5,8-11,17H2,1H3,(H,35,36)(H,37,38)
InChIKey: XDJGNPSZQSWJCV-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 135567296
CAS Number: 1421502-62-6
TTD ID: D0DK5X

References

1	ClinicalTrials.gov (NCT01981681) A Phase 1 Study To Evaluate Tolerability, Safety, And Pharmacokinetics Of Topical PF-06263276 In Healthy Subjects. U.S. National Institutes of Health.